iASPP is a member of the apoptosis-stimulating protein of p53 (ASPP) family and an evolutionarily conserved inhibitor of p53. Higher levels of iASPP proteins were examined in paraffin-embedded sections collected from 30 patients with prostate cancer using an immunohistochemical method. We found that specially knocking down iASPP with lentivirus-mediated small interfering RNA inhibited the growth, in vitro colony-forming capacity and in vivo tumorigenesis of p53-defective prostate cancer cells. Importantly, inhibition of iASPP induced cell apoptosis, which confers the inhibitory effect on cell survival. We conclude that iASPP is essential for prostate cancer cellular proliferation and survival and may be a potential target for the gene therapy for prostate cancer.
Introduction
Prostate cancer is the most commonly diagnosed malignancy in men and the second most common cause of cancer-related deaths. 1, 2 The large majority of patients, however, relapse within a few years of treatment due to the emergence of a castration-resistant clone of prostate cancer cells. Current methods of treating advanced metastatic disease often prove to be insufficient in the long term. There is a great need for novel therapeutic strategies that target the molecular basis of castrationresistant, chemo-resistant prostate cancer.
The p53 protein has a critical role in regulation of cell proliferation mainly by induction of growth arrest or cell apoptosis, thereby preventing the propagation of cells that may be undergoing malignant transformation. 3 The recently discovered apoptosis-stimulating protein of p53 (ASPP) family consists of three members, ASPP1, ASPP2 and iASPP. They regulate the proteins that are having key roles in controlling apoptosis (p53, Bcl-2 and RelA/p65) and cell growth (APCL, PP1). 4 Among the ASPP family, ASPP1 and ASPP2 enhance the ability of p53 to stimulate specifically the expression of pro-apoptotic target genes but not genes involved in cell-cycle arrest. 5, 6 Although the inhibitory member of ASPP family inhibits p53-mediated apoptosis. 7 Further investigation demonstrates that iASPP, the most evolutionary conserved member, is the only ASPP family member found from worm to human. 8 Inhibition of iASPP by RNA interference or antisense RNA in C. elegans or human cells, respectively, induces p53-dependent apoptosis, which could provide an important new strategy for treating tumor expressing wild-type p53. 8 Increased expression of iASPP also confers resistance to ultraviolet radiation and to cisplatin-induced apoptosis. The expression of iASPP is upregulated in human breast carcinomas expressing wild-type p53 and normal levels of ASPP1 and ASPP2, and downregulation of iASPP expression in MCF-7 breast cancer cells causes the increase in cells apoptosis rate. 9 However, the loss of p53 protein is a key event in the pathogenesis of a wide variety of human malignancies including prostate cancer. 10 At present, it is still not clear whether iASPP is relevant to p53-deficient human prostate cancer. The aim of this study was to examine the role of iASPP in the proliferation and tumorigenesis of prostate cancer cells that do not express p53 (PC-3) or express mutant p53 (DU145) 11, 12 by lentivirus-mediated RNA interference.
Materials and methods

Cells culture
PC-3 and DU145, human prostate cancer cell lines, were purchased from ATCC (Manassas, VA, USA) and maintained in RPMI1640 containing 10% fetal bovine serum in a humidified atmosphere of 5% CO 2 at 371C.
Immunohistochemistry
A total of 30 patients with prostate cancer were recruited from the outpatient and inpatient services at the Third Affiliated Hospital of Sun Yat-Sen University. The experimental protocols were approved by the Ethics Committee of the Third Affiliated Hospital of Sun YatSen University. Sections prepared from the tumor tissues and adjacent tissues were probed with 1:500 rabbit antiiASPP (Poly-antibody, Rockland, Gilbertsville, PA, USA) followed by incubating with biotinylated goat anti-rabbit immunoglobulins (Santa Cruz Biotechnologies, Santa Cruz, CA, USA). The proportion of positive tumor cells and the average intensity of the positive tumor cells were estimated following previously described immunohistochemical scores. 13 
Lentivirus package and infection
To generate iASPP-specific short hairpin RNA (shRNA)-expressing lentivirus, the target sequence (5 0 -CACATGGATCTGAAGCAGA-3 0 ) for human iASPP (NM_006663) was identified. The negative control construct having no homology with human genome was created by a scrambled sequence (5 0 -AATGTACTGCGCG TGGAGA-3 0 ). The sequences were cloned into the Age I and EcoR I sites of the pGCSIL-GFP plasmid (GeneChem, Shanghai, China) to generate pGCSIL-GFP-iASPP or pGCSIL-GFP-Ctr, respectively. pGCSIL-GFP-iASPP or pGCSIL-GFP-Ctr, together with the plasmids containing the imperative elements for virus packaging, were co-transfected into 293T cells with lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA). The culture supernatants were harvested and ultracentrifuged. The lentivirus expressing iASPP shRNA and control lentivirus were termed as Lv-iASPP-shRNA and Lv-Ctr, respectively. PC-3 and DU145 cells were plated in 6-well plates to reach 40-50% confluency. Appropriately titered lentivirus was added at moi of 20 and incubated at 37 1C. ÀDDCt method. 14 
Western blotting
Cells were lysed using lysis buffer (0.1% sodium dodecyl sulfate, 1% NP-40, 50 mM HEPES, pH 7.4, 2 mM EDTA, 100 mM NaCl, 5 mM sodium orthovanadate, 40 mM p-nitrophenyl phosphate, and 1% protease inhibitor mixture set I) and centrifuged. The supernatant was collected and denatured. Proteins were separated in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and blotted onto polyvinylidene difluoride membrane. The blot was blocked for 1.5 h at room temperature in 5% bovine serum albumin, followed by overnight incubation at 41C with indicated antibodies. Membranes were rinsed and incubated for 1 h with the correspondent peroxidase-conjugated secondary antibodies. Chemiluminent detection was performed with the ECL kit (Pierce Chemical, Rockford, IL, USA).
Cell proliferation assay
The proliferation of PC-3 and DU145 cells infected with Lv-iASPP-shRNA or Lv-Ctr for 3 days were evaluated by a modified MTT and BrdU incorporation assays. 15 Cells in exponential growth were plated at a final concentration of 2 Â 10 3 cells per well in 96-well plates. Cell viability was assessed by MTT assay after 1, 2, 3, 4 and 5 days of seeding. DNA synthesis in proliferating cells was determined by using BrdU incorporation assay 24 and 48 h after seeding. The optical density of each well was measured with an ELISA reader.
Colony formation assay
The effect of iASPP silence on the colony formation of PC-3 and DU145 cells was analyzed by colony formation assay. Parent cells, Lv-iASPP-shRNA or Lv-Ctr infected cells at 6-well plate (200 cells per well) were cultured for 2 weeks. The cell colonies were washed, fixed and stained with Giemsa. Individual colonies with more than 50 cells were counted.
Detection of apoptosis by flow cytometry
Cells were infected with individual lentivirus for 3 days and were subjected with flow cytometry assay using a Annexin V Apoptosis Detection Kit APC (eBioscience, San Diego, CA, USA). Briefly, a total of 1 Â 10 6 cells were resuspended in 1 ml of staining buffer after extensive washing with ice-cold phosphate-buffered saline and treated with 5 ml of annexin V-APC for 15 min in the dark at room temperature. Fluorescence-activated cell sorting analysis for annexin-V staining was performed by flow cytometer (BD Biosciences, San Jose, CA, USA). Three independent experiments were performed in triplicate.
Tumorigenesis assay
The influence of iASPP silence on the tumor development of prostate tumor in vivo was examined. Parent DU145 cells, Lv-iASPP-shRNA or Lv-Ctr infected cells were injected subcutaneously into 4-week-old Balb/c nude mice (n ¼ 10 per group, Shanghai SLAC laboratory Animal, Shanghai, China) at 5 Â 10 6 per mouse. The development and growth of solid tumors were monitored by measuring tumor size using a vernier caliper in a blinded manner every 5 days for a 27-day period. The tumor volume was calculated using a standard formula: tumor volume (mm 
Results
Higher levels of iASPP expression in human prostate cancer tissues
The expression of iASPP in prostate cancer from 30 radical prostatectomy specimens was determined by immunohistochemical assay (Figure 1 , Table 1 ). Higher levels of iASPP were anoted in areas of prostate cancer, compared with paired adjacent normal tissues (53.3 vs 23.3%), indicating that upregulation of iASPP may contribute to the pathogenesis of human prostate cancer.
Reduction of iASPP mRNA and protein expression by lentivirus-mediated shRNA
After the cells were infected with lentivirus for 3 days, GFP-expressing cells was observed, which verified the high effciency of lentivirus infection (Figure 2a) . The mRNA level of PC-3 cells infected with Lv-iASPPshRNA was downregulated compared with the control cells infected with Lv-Ctr (Po0.05), and there is no obvious difference between the parent cells and the Lv-Ctr-infected cells (Figure 2b ). In accordance with the silence of mRNA expression, iASPP protein was also downregulated in PC-3 cells following Lv-iASPP-shRNA infection (Figure 2c ). Thus, iASPP shRNA could downregulate iASPP expression level efficiently.
Effect of downregulated iASPP expression on proliferative potency, colony-forming capacity and apoptosis
Following 5 days of incubation, the proliferation of Lv-Ctr-infected PC-3 cells was indistinguishable from its parent cells and showed strong proliferation. However, the proliferation of Lv-iASPP-shRNA-treated cells was much inhibited, evidenced by that the viable cells were reduced by about 80% on day 5 compared with the control groups ( Figure 3a) . Next, the effect of the iASPP knockdown on the DNA synthesis rate was examined. As shown in Figure 3b , after 48 h of incubation, the rate of DNA synthesis in Lv-iASPPshRNA-infected cells was significantly suppressed by 39% in the Lv-iASPP-shRNA-infected PC-3 cells.
The effect of iASPP downregulation on the in vitro tumorigenesis was examined by colony formation in PC-3 cells. As can be seen in Figures 3d and e , Lv-iASPPshRNA-infected cells showed significantly lower colony number than the control cells (Po0.05), whereas the colony numbers showed no obvious difference between the parent cells and the Lv-Ctr-infected cells.
Further determination about cell apoptosis elucidated the strong role of iASPP in cell survival or apoptosis. We found that the percentage of apoptotic cells following iASPP knockdown was significantly increased, comparing with the control cells (Figure 3f) .
Another prostate cancer cell line that express mutant p53 (DU145 cells) was also used in Lv-iASPP-shRNA infection. Real-time PCR data supported the specific iASPP knockdown in DU145 cells (Figure 4a) . Similarly, decreased cell viability (Figure 4b ), DNA synthesis Inhibitory member of ASPP promotes growth and tumorigenesis B Zhang et al (Figure 4c ), as well as in vitro colony formation (Figure 4d ) of DU145 cells was found, which further confirmed the functional role of iASPP in modulating prostate cancer proliferation.
Impact of downregulated iASPP expression on the in vivo tumorigenesis
The developed solid tumors in each group were visible about 12 days post inoculation and grew rapidly later in both control groups. In contrast, the development of Lv-iASPP-shRNA-related solid tumors grew slowly (Figure 5a ) and the mean volume of tumors in the iASPP knockdown group decreased by about 75%, as compared with that in control groups ( Figure 5b) . As a result, the mean weight of tumors in the iASPP knockdown group was significantly lower than that in control groups (Figures 5c and d, Po0.05) . Collectively, these data evidenced that downregulation of iASPP expression mitigated the in vivo tumorigenesis of DU145 cells. have been engaged in the therapeutics for human malignancy recently. 16 The treatment of cancer using small interfering RNAs strongly depends on the efficiency of gene transfer. Lentivirus, featured by its long incubation period, is being developed for use as a safe vector for gene transfer. 17 Thus, the combination of lentivirus and RNA interference might provide a novel therapeutic strategy for prostate cancer gene therapy. 18 Presently, it is still not clear whether iASPP expression is related to human prostate cancer proliferation and Inhibitory member of ASPP promotes growth and tumorigenesis B Zhang et al progression. Our data revealed that high levels of iASPP expression were detected in tumor tissues compared with the adjacent prostate tissues, implying the important role of iASPP in the development of prostate cancer. As the loss of p53 function happened in more than half of all human cancers, we then examine the role of iASPP in human prostate cancer cells that lack p53 function. iASPP shRNA-expressing lentivirus was generated and infected into both p53-defective PC-3 and DU145 cells. We found that downregulation of endogenous iASPP greatly inhibited the viability, DNA synthesis, colony formation and the xenograft tumor formation in nude mice. More importantly, the impaired expression of iASPP resulted in enhanced cell apoptosis. These findings demonstrated that downregulation of iASPP expression inhibited the proliferation of p53-defective prostate cells via inducing apoptosis. Thus, shRNA-expressing lentivirus-mediated downregulation of iASPP may be a useful try in treatment of human prostate cancer.
It was reported that the p53 tumor suppressor had an important role in regulating the proliferation of cells through either cell-cycle arrest or apoptosis.
19 ASPP1 and ASPP2 could enhance the ability of p53 to stimulate specifically the expression of pro-apoptotic target genes but not genes involved in cell-cycle arrest, 5, 6 whereas iASPP inhibited p53-mediated apoptosis. However, our results implied that the role of iASPP in inducing apoptosis and modulating proliferation is irrespective of p53 status. A recent study reported that a p53-derived peptide that targets iASPP can effectively trigger tumor cell death by a p73-dependent mechanism. These findings promoted further study of iASPP targeting as a therapeutic strategy to activate p73. 20 In this regard, the interaction of iASPP and other members of the p53 family that are involved in the development and progression of human prostate cancer remains to be determined.
In conclusion, iASPP was highly expressed in prostate tumor tissues. Downregulation of endogenous iASPP expression by lentivirus-mediated shRNA inhibited proliferation and tumorigenesis and increased apoptosis of p53-defective prostate cancer cells. Thus, we conclude that iASPP has a vital role in prostate cancer cell proliferation.
